A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)

NCT06144086 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Liver Cirrhosis

Interventions

DRUG: Foscenvivint

Sponsor

Kiminori Kimura, MD

Collaborators

[object Object]